insights_auto
Why is ALNOV down 2.27%?
Dive Deeperchevron_right
ALNOV:EPA
Novacyt SA
€0.43
arrow_downward
-2.27%(-0.0100) 1D
ኖቬም 12, 5:35:24 ከሰዓት ጂ ኤም ቲ+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNOV...
Open
€0.44
High
€0.44
Low
€0.42
Mkt. cap
31.28 ሚ
Avg. vol.
165.49 ሺ
Volume
355.51 ሺ
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.37
Shares outstanding
72.59 ሚ
No. of employees
228
Open
€0.44
High
€0.44
Low
€0.42
Mkt. cap
31.28 ሚ
Avg. vol.
165.49 ሺ
Volume
355.51 ሺ
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.37
Shares outstanding
72.59 ሚ
No. of employees
228
News stories
From web sources and news partners
Proactive financial news
·
ከ1 ቀን በፊት
Novacyt shares rise over 6% after Australian approval for chemotherapy toxicity test
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA
CEODavid Allmond
Employees228
Founded3 ጁላይ 2006
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitenovacyt.com